Slingshot members are tracking this event:

Regeneron Pharmaceuticals (REGN) Phase 2 PD-1 antibody trial in non-small cell lung cancer set to begin in 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
REGN Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Non-small Cell Lung Cancer, Pd-1, Phase 2